Bristol-Myers to shed psoriasis drug to win approval for Celgene deal
June 24, 2019 at 10:06 AM EDT
Bristol-Myers Squibb Co. said it would divest itself of Otezla, a psoriasis treatment owned by Celgene Corp., to win approval from regulators and help smooth the path for the companies’ pending merger.
